FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. 20549 |
|-------------|------------|
|-------------|------------|

| Check this box if no longer subject | STATEMENT C |
|-------------------------------------|-------------|
| to Section 16. Form 4 or Form 5     |             |
| obligations may continue. See       |             |
| Instruction 1(b).                   | Filed nursi |

## OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Johnston Lori A</u>  |  |            |         |  |  | 2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN ] |  |   |       |   |                            |        |   | Chec   | k all app<br>Direc  |   | ng Perso   | 10% O\                                  |            |
|--|--|------------|---------|--|--|--|--|---|-------|---|----------------------------|--------|---|--|---|---|--|---|------------|
| (Last) (First) (Middle) ONE AMGEN CENTER DRIVE                   |  |            |         | 3. Date of Earliest Transaction (Month/Day/Year) 03/19/2021                          |  |  |  |   |       |   |                            |        | X   | below)   |   | below)<br>P, HR   |  | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |            |
| (Street) THOUS   | AND CA   | <b>A</b> 9 | )1320-1 | 1799   | 4. If Amendment, Date of Original Filed (Month/Day/Year) |  |  |   |       |   |                            |        |   | 6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person |   |   |  |   |            |
| (City)   | (Sta   | ate) (2    | Zip)    |  |  |  |  |   |       |   |                            |        |   |  |   |   |  |   |            |
|  |  | Table      | l - No  | n-Deriva   | tive S   | Secui  | rities   | Acq   | uired | l, Dis  | posed of                   | , or E | Benefic   | ially  | / Own   | ed  |  |   |            |
| 1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day) |  |            |         | Execution Date,  |  |  | ate,   | 3.<br>Transaction<br>Code (Instr. 8)  4. Securities Acquired (Disposed Of (D) (Instr. 3) 5) |       |   | red (A) or<br>estr. 3, 4 a | nd     | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported |  | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) |   | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership                |   |            |
|  |  |            |         |  |  |  |  |   | Code  | v   | Amount                     | (A) o  | Price   |  | Transa  | action(s)<br>. 3 and 4)   |  |   | (Instr. 4) |
| Common Stock 03/19/2   |  |            |         |  | 2021   |  |  |   | F     |   | 2,803                      | D      | \$244   | 4.42   | 35,104(1)(2)  |   | I  | D                                       |            |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |            |         |  |  |  |  |   |       |   |                            |        |   |  |   |   |  |   |            |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)              | tive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any   |            |         | Transaction Code (Instr. 8)  Securiti Acquire (A) or Dispose of (D) (Instr. 3 and 5) |  | rative<br>rities<br>ired<br>r<br>osed<br>)                     | 6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Date Expiration Exercisable Date |   |       | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of Title Shares |                            | _      |   | 9. Number<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 4)                           | y Di<br>or<br>(I)   | ).<br>wnership<br>orm:<br>irect (D)<br>r Indirect<br>I (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |            |

## **Explanation of Responses:**

- 1. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2.573 on 11/1/2021, 2.574 on 11/1/2022 and 2.652 on 11/1/2023; and 2.961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1.007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- 2. These shares include 742 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

/s/ Lori A. Johnston

03/22/2021

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.